Skip to Content

BCR-ABL tyrosine kinase inhibitors

What are BCR-ABL tyrosine kinase inhibitors

BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death. BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.

A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).

Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.

BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.

List of BCR-ABL tyrosine kinase inhibitors:

Filter by:
Drug Name DownUp( View by: Brand | Generic ) Reviews Ratings DownUp
dasatinib systemic (Pro, More...)
14 reviews
   
9.1
imatinib systemic (Pro, More...)
33 reviews
   
9.1
nilotinib systemic (Pro, More...)
23 reviews
   
8.0
ponatinib systemic (Pro, More...)
2 reviews
   
3.0
bosutinib systemic (Pro, More...)
0 reviews
   
0.0
Hide